Anti-CD19 CAR / NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28-4-1BB-CD3ζ)
Anti-CD19 CAR/NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28-4-1BB-CD3ζ) is a stable cell line expressing an anti-CD19 CAR and an NFAT-dependent luciferase reporter. The reporter cell line has been validated for anti- CD19 expression by flow cytometry, and for luciferase reporter activation by target cells, including the CD19 CHO cell line. Anti-CD19 CAR consists of the anti-CD19 scFv linked to 3rd generation CAR containing the CD28, 4-1BB co-stimulatory domains and the CD3ζ signaling domain.
The cell line can be used for primary screening and functional validation of anti-CD19 CAR construct and lentivirus before testing is performed in primary T cells.
Figure 1: Lenti-vector used to generate anti-CD19 CAR lentivirus.
Figure 2. Schematic of anti-CD19 CAR.
Anti-CD19 (scFv) is linked to the 3rd generation CAR with CD28 transmembrane and costimulatory domains, 4-1BB, and CD3ζ components.
Interested in screening and profiling anti-CD19 CAR cells using your cell models without the need to purchase and license the cell line? Check out our Cell Signaling Pathway Screening.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
Media Required for Cell Culture
| Name | Ordering Information |
| Thaw Medium 2 | BPS Bioscience #60184 |
| Growth Medium 2H | BPS Bioscience #79784 |
Materials Required for Cellular Assay
| Name | Ordering Information |
| Thaw Medium 2 | BPS Bioscience #60184 |
| Thaw Medium 3 | BPS Bioscience #60186 |
| CD19, Fc-Fusion (IgG1), Avi-Tag, Biotin labeled | BPS Bioscience #79475 |
| CD19 CHO Recombinant Cell Line | BPS Bioscience #79561 |
| NFAT Reporter (Luc)- Jurkat Recombinant Cell Line | BPS Bioscience #60621 |
| Anti-CD19 CAR negative control/ NFAT (Luciferase) Reporter Jurkat Cell Line | BPS Bioscience #79854 |
| Empty vector control – CHO-K1 Recombinant Cell line | BPS Bioscience #60545 |
| PE Streptavidin | Biolegend #405203 |
| 7-AAD | BioLegend #420403 |
| ONE-Step™ Luciferase Assay System | BPS Bioscience #60690 |
| Luminometer |
The cell line has been screened to confirm the absence of Mycoplasma species.
CD19 (also known as Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) is a glycoprotein expressed at the surface of B lymphocytes through most phases of B cell maturation. It is strictly required for B cell terminal differentiation. Mutations in the CD19 gene cause severe immune-deficiency syndromes associated with impaired antibody production such as CVID3 (common variable immuno-deficiency 3). The majority of B cell malignancies express normal to high levels of CD19, making it a nearly ideal target for cancer immunotherapy. Blinatumomab, a CD19/CD3 bi-specific T cell engager (BiTE) has been approved for relapsed/refractory B precursor ALL (Acute lymphoblastic leukemia) and CD19 was the target of the first approved CAR-T cell therapy. Studies of CD19 function and expression profiles will continue to broaden our knowledge and support broader applications in cancer therapy.
1. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies.Wang et al. J Hematol Oncol. 2019 Jun 11;12(1):59-78.
2. Chimeric antigen receptor T cell therapy for multiple myeloma. Hasegawa et al. Inflamm Regen. 2019 Jun 4;39:10-14.
3. Novel targets for the treatment of relapsing multiple myeloma. Giuliani et al. Expert Rev Hematol. 2019 Jun 3:1-16.
4. Anti-CD19 antibodies in the future management of multiple myeloma. Gavriatopoulou et al. Expert Rev Anticancer Ther. 2019 Apr;19(4):319-326.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.